FY2026 EPS Estimate for Rein Therapeutics Lowered by Analyst

Rein Therapeutics Inc. (NASDAQ:RNTX) – Analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of Rein Therapeutics in a report issued on Thursday, April 2nd. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($1.63) per share for the year, down from their previous estimate of ($0.80). The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Rein Therapeutics’ FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.46) EPS and FY2029 earnings at ($1.22) EPS.

A number of other research analysts also recently commented on RNTX. downgraded shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Citigroup downgraded shares of Rein Therapeutics to a “hold” rating in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Price Performance

Shares of RNTX opened at $1.58 on Tuesday. The firm has a 50-day moving average of $1.24 and a 200-day moving average of $1.30. Rein Therapeutics has a one year low of $1.02 and a one year high of $2.40. The company has a market cap of $44.30 million, a PE ratio of -0.81 and a beta of 1.40.

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.12).

Institutional Trading of Rein Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Gleason Group Inc. bought a new stake in shares of Rein Therapeutics in the third quarter valued at about $26,000. Susquehanna International Group LLP bought a new stake in shares of Rein Therapeutics in the third quarter valued at about $35,000. HRT Financial LP bought a new stake in shares of Rein Therapeutics in the fourth quarter valued at about $38,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Rein Therapeutics in the second quarter valued at about $68,000. Finally, Jane Street Group LLC bought a new stake in Rein Therapeutics in the 4th quarter valued at about $72,000. Institutional investors own 90.89% of the company’s stock.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.